|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-3-30
|
|
pubmed:abstractText |
Multiple myeloma is a plasma cell malignancy characterized by the development of osteolytic lesions leading to bone pain, pathologic fractures, and hypercalcemia. Osteoprotegerin (OPG) is a potent inhibitor of osteoclast differentiation and activation, but is limited as a therapeutic agent due to its short circulating half-life. In order to overcome these limitations, the therapeutic effects of native OPG gene transfer are examined.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Recombinant,
http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Osteoprotegerin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cytoplasmic and Nuclear,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFRSF11B protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tnfrsf11b protein, mouse
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0301-472X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
351-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15050745-Animals,
pubmed-meshheading:15050745-Bone Density,
pubmed-meshheading:15050745-Cell Line, Tumor,
pubmed-meshheading:15050745-DNA, Antisense,
pubmed-meshheading:15050745-DNA, Recombinant,
pubmed-meshheading:15050745-Gene Therapy,
pubmed-meshheading:15050745-Genetic Vectors,
pubmed-meshheading:15050745-Glycoproteins,
pubmed-meshheading:15050745-Lac Operon,
pubmed-meshheading:15050745-Lentivirus,
pubmed-meshheading:15050745-Mice,
pubmed-meshheading:15050745-Multiple Myeloma,
pubmed-meshheading:15050745-Neoplasm Transplantation,
pubmed-meshheading:15050745-Osteoclasts,
pubmed-meshheading:15050745-Osteolysis,
pubmed-meshheading:15050745-Osteoprotegerin,
pubmed-meshheading:15050745-Pilot Projects,
pubmed-meshheading:15050745-Receptors, Cytoplasmic and Nuclear,
pubmed-meshheading:15050745-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:15050745-Transduction, Genetic,
pubmed-meshheading:15050745-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts.
|
|
pubmed:affiliation |
Molecular Medicine Program, Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minn. 55905, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
